TRIPLETE: Phase III Trial of First-line mFOLFOXIRI + Panitumumab vs mFOLFOX6 + Panitumumab in RAS/BRAF Wild-Type mCRC

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
Intensification of first-line chemotherapy with mFOLFOXIRI in combination with panitumumab did not improve response rate, depth of response, or PFS in patients with RAS and BRAF wild-type mCRC.
Format: Microsoft PowerPoint (.ppt)
File Size: 173 KB
Released: June 9, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings